Description
***********SPANISH LANGUAGE EXAM******************
2023 Provider Renewal Opens Soon
Current Pediatric Chemotherapy/Biotherapy providers whose status expires December 31, 2023 will be able to renew their provider status October 1– December 15, 2023. The provider renewal program will close at 11:59pm Eastern Time on December 15, 2023.
You must be logged in to access the renewal product. Our systems have been upgraded. If you haven’t logged in since June 1, 2023, please select the “Sign In” button and select “Forgot Password” to reset your password and reactivate your account. If you have forgotten your login information or need assistance, please contact us at education@aphon.org or via phone at +1.703.506.3275 or 1.855.202.9760 (US Only)
The renewal fee must be submitted online using a valid credit card by adding the product to your cart and completing the checkout process. Submitting payment may take a few seconds, please only hit the button once.
Providers from low income countries should email education@aphon.org for special pricing.
To access the renewal exam, ensure you are logged in, then visit My Courses in the ACE Center. The renewal PDF content and a link to the renewal exam will be available in this area.
You may log into the renewal system and view the downloadable PDF content as often as you like until you are ready to take the exam.
JOPHON CNE (May/June 2023): Pediatric Chemotherapy Infusions in Outpatient Examination Rooms: A Novel Patient Care Approach
JOPHON CNE (Sep/Oct 2022): The Experience of Children With Neuroblastoma and Their Parents During Single-Room Isolation for I-Metaiodobenzylguanidine Therapy: A Qualitative Descriptive Study
JOPHON CNE (Nov/Dec 2021): Evidence-Based Recommendations for Nurse Monitoring and Management of Immunotherapy-Induced Cytokine Release Syndrome
JOPHON CNE (Mar/Apr 2022): Nursing Presence in Pediatric Oncology: A Scoping Review
JOPHON CNE (2023 Jul-Aug) – Art Unfolds Words: Expressing Hope Through Creative Art Among Adolescents and Young Adults Who Have Advanced Cancer


